Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

about

Improvement of Chronic Idiopathic Urticaria With Levothyroxine: A Case Report and Review of Literature

P2860

Q58564273-F890C786-9241-4CEE-9401-F90D3596396B

P2860

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

Item

http://www.wikidata.org/entity/Q52661824

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

@en

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

@nl

type

Item

label

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

@en

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

@nl

prefLabel

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

@en

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

@nl

P1476

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

@en

P2093

Abhishek De

http://www.w3.org/2001/XMLSchema#string

Bela Shah

http://www.w3.org/2001/XMLSchema#string

D S Krupashankar

http://www.w3.org/2001/XMLSchema#string

Kiran Godse

http://www.w3.org/2001/XMLSchema#string

Mukesh Girdhar

http://www.w3.org/2001/XMLSchema#string

Murlidhar Rajagopalan

http://www.w3.org/2001/XMLSchema#string

Vijay Zawar

http://www.w3.org/2001/XMLSchema#string

P2860

Histamine H2-receptor antagonists for urticaria

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.

Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report.

Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.

New insights into the second generation antihistamines.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.

Methotrexate-responsive chronic idiopathic urticaria: a report of two cases.

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

P304

2-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJD.IJD_308_17

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29527019

http://www.w3.org/2001/XMLSchema#string

P932

5838750

http://www.w3.org/2001/XMLSchema#string

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

about

P2860

P2860

Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932